Table 2.
Overall survival and endocan levels (ng/mg protein) in patients studied here.
| Number | Endocan levels in the groups | Follow-up (months) MGs/LGGs/HGGs |
|||
|---|---|---|---|---|---|
| Controls | MGs | LGGs | HGGs | ||
| 1 | 8.12 | 12.27 | 14.55 | 15.62 | 36/24/9∗ (D) |
| 2 | 9.76 | 14.50 | 12.65 | 19.05 | 36/48/36 |
| 3 | 11.08 | 12.98 | 13.20 | 22.30 | 12/36/60 |
| 4 | 10.91 | 11.62 | 18.90 | 17.50 | 36/12/12∗ (D) |
| 5 | 10.72 | 12.02 | 11.77 | 14.36 | 16/48/15∗ (D) |
| 6 | 7.92 | 10.91 | 12.27 | 12.78 | 60/13/36 |
| 7 | 8.41 | 9.23 | 10.78 | 18.90 | 24/24/12∗ (D) |
| 8 | 8.77 | 11.77 | 12.98 | 14.55 | 36/14/15∗ (D) |
| 9 | 11.20 | 10.72 | 9.25 | 16.71 | 36/15/18∗ (D) |
| 10 | 10.32 | 9.21 | 17.62 | 17.62 | 36/18/12∗ (D) |
| 11 | 8.41 | 11.21 | 10.91 | 15.02 | 36/24/30∗ (D) |
| 12 | 7.65 | 12.36 | 9.23 | 16.71 | 23/24/30 |
| 13 | 12.04 | 14.32 | 14.52 | 12.65 | 13/24/42 |
| 14 | 8.62 | 10.27 | 14.60 | 10.91 | 23/16/18 |
| 15 | 11.08 | 11.41 | 17.30 | 18.09 | 12/36/12∗ (D) |
| 16 | — | 14.55 | 14.50 | 17.52 | 13/24/13∗ (D) |
| 17 | — | 14.36 | 18.62 | 15.94 | 24/19/12∗ (D) |
| 18 | — | 12.50 | 16.02 | 15.94 | 36/26/15∗ |
| 19 | — | 10.91 | 14.50 | 14.20 | 12/13/16∗ |
| 20 | — | 10.65 | — | 17.60 | 24/—/18 |
D: died; HGGs: high-grade gliomas; LGGs: low-grade gliomas; MGs: meningiomas.
∗denotes grade-IV astrocytoma (glioblastoma multiforme).